全国性房颤队列中抗血栓治疗使用与COVID-19结局的评估
88.0%有既往抗血栓治疗,3.8%发生COVID-19住院,2.2%死亡。既往抗血栓治疗与死亡 odds 降低相关(OR=0.92),但与住院 odds 升高相关(OR=1.20)。
要点
- 房颤合并高卒中风险患者中,既往抗血栓治疗与COVID-19死亡风险降低相关。
- 既往抗血栓治疗与COVID-19住院风险升高相关,需警惕因果解释。
- 直接口服抗凝药较华法林与住院风险降低相关,死亡风险无差异。
核心结论
- 既往抗血栓治疗可能与COVID-19死亡 odds 降低相关,但非因果证据,支持改善房颤患者抗血栓覆盖。
研究设计与样本
- 采用逻辑回归分析抗血栓使用相关因素,逻辑和Cox回归分析COVID-19住院和死亡差异。
主要发现
- 既往抗血栓治疗与死亡 odds 降低相关(OR=0.92,95%CI 0.87-0.96),与住院 odds 升高相关(OR=1.20,95%CI 1.15-1.26)。
- 抗凝药 vs 抗血小板药与死亡 odds 降低相关(OR=0.93,95%CI 0.87-0.98),与住院 odds 升高相关(OR=1.17,95%CI 1.11-1.24)。
- 直接口服抗凝药 vs 华法林与住院 odds 降低相关(OR=0.86,95%CI 0.82-0.89),死亡无差异(OR=1.00,95%CI 0.95-1.05)。
临床怎么用
- 对CHA2DS2-VASc评分≥2的房颤患者,应评估并优化抗血栓治疗覆盖。
- 既往抗血栓治疗可能改善COVID-19死亡结局,但需结合住院风险综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate antithrombotic (AT) use in individuals with atrial fibrillation (AF) and at high risk of stroke (CHA2DS2-VASc score ≥2) and investigate whether pre-existing AT use may improve COVID-19 outcomes. METHODS: Individuals with AF and CHA2DS2-VASc score ≥2 on 1 January 2020 were identified using electronic health records for 56 million people in England and were followed up until 1 May 2021. Factors associated with pre-existing AT use were analysed using logistic regression. Differences in COVID-19-related hospitalisation and death were analysed using logistic and Cox regression in individuals with pre-existing AT use versus no AT use, anticoagulants (AC) versus antiplatelets (AP), and direct oral anticoagulants (DOACs) versus warfarin. RESULTS: From 972 971 individuals with AF (age 79 (±9.3), female 46.2%) and CHA2DS2-VASc score ≥2, 88.0% (n=856 336) had pre-existing AT use, 3.8% (n=37 418) had a COVID-19 hospitalisation and 2.2% (n=21 116) died, followed up to 1 May 2021. Factors associated with no AT use included comorbidities that may contraindicate AT use (liver disease and history of falls) and demographics (socioeconomic status and ethnicity). Pre-existing AT use was associated with lower odds of death (OR=0.92, 95% CI 0.87 to 0.96), but higher odds of hospitalisation (OR=1.20, 95% CI 1.15 to 1.26). AC versus AP was associated with lower odds of death (OR=0.93, 95% CI 0.87 to 0.98) and higher hospitalisation (OR=1.17, 95% CI 1.11 to 1.24). For DOACs versus warfarin, lower odds were observed for hospitalisation (OR=0.86, 95% CI 0.82 to 0.89) but not for death (OR=1.00, 95% CI 0.95 to 1.05). CONCLUSIONS: Pre-existing AT use may be associated with lower odds of COVID-19 death and, while not evidence of causality, provides further incentive to improve AT coverage for eligible individuals with AF.
引用
- Handy, Banerjee, Wood, et al. Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort. Heart. 2022. PMID: 35273122. doi:10.1136/heartjnl-2021-320325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。